Development of Predictive Biomarkers and Novel Approached to Therapy in Breast Cancer
Conditions
Breast Cancer
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case-Crossover, Time Perspective: Cross-Sectional
Overall Status
Recruiting
Summary
Breast cancer is a common malignancy world-wide, and is the commonest female malignancy in Singapore, with rising trends in incidence over the last 2 decades. While there have been improvements in treatment, mortality from breast cancer remains significant. Development of biomarkers to predict treatment response and toxicity to anti-cancer agents can rationalize the choice of therapy for the individual patients to optimize treatment outcome and to reduce unnecessary toxicities. Development of novel therapies or novel approaches to therapy is also critical to improve the treatment armamentarium in breast cancer. These research strategies will have an significant impact on breast cancer treatment both in Singapore as well as globally.
Criteria for eligibility
Healthy Volunteers: Accepts Healthy Volunteers
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

This program will recruit mainly cancer patients, predominantly breast cancer patients. The exact inclusion criteria will vary between each individual study. Each individual component study will be submitted to DSRB for separate approval, along with the study protocol and patient informed consent sheet.

Exclusion Criteria:

The exact exclusion criteria will vary between each individual study. Each individual component study will be submitted to DSRB for separate approval, along with the study protocol and patient informed consent sheet.
Location
National University Hospital Singapore
Singapore, Singapore
Status: Recruiting
Contact: Soo Chin Lee, MBBS, MRCP - 65 6772 4629 - soo_chin_lee@nuhs.edu.sg
Start Date
January 2010
Sponsors
National University Hospital, Singapore
Source
National University Hospital, Singapore
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page